Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7426-7436

  Jensen, Sanne B ^a   Serre, Stéphanie B N ^a   Humes, Daryl G ^a   Ramirez, Santseharay ^a   Li, Yi Ping ^a   Bukh, Jens ^a   Gottwein, Judith M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARTIC ACID; ASUNAPREVIR; BOCEPREVIR; DELDEPREVIR; FALDAPREVIR; GLUTAMINE; GRAZOPREVIR; LYSINE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PARITAPREVIR; PROTEINASE; SIMEPREVIR; TELAPREVIR; VANIPREVIR; ANTIVIRUS AGENT; MK-5172; NS3 PROTEIN, HEPATITIS C VIRUS; OLIGOPEPTIDE; PROTEINASE INHIBITOR; QUINOXALINE DERIVATIVE; RECOMBINANT PROTEIN; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CONCENTRATION RESPONSE; GENETIC VARIABILITY; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; INDUCED RESISTANCE; MINIMUM PLASMA CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ANTIVIRAL RESISTANCE; CELL LINE; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HUMAN; METABOLISM;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HUMANS; OLIGOPEPTIDES; PROTEASE INHIBITORS; QUINOXALINES; RECOMBINANT PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84954549573     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01953-15     Document Type: Article

References (58)

1. Pawlotsky JM. 2014. New hepatitis C therapies: The toolbox, strategies, and challenges. Gastroenterology 146: 1176-1192. http://dx.doi.org/10 .1053/j.gastro.2014.03.003.
2. Franco S, Tural C, Nevot M, Molto J, Rockstroh JK, Clotet B, Martinez MA. 2014. Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man. Gastroenterology 147: 599-601. http://dx.doi.org/10 .1053/j.gastro.2014.05.010.
3. Moradpour D, Penin F. 2013. Hepatitis C virus proteins: From structure to function. Curr Top Microbiol Immunol 369: 113-142. http://dx.doi.org/10.1007/978-3-642-27340-7-5.
4. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology 59: 318-327. http://dx.doi.org/10.1002/hep.26744.
5. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. 2011. Differential efficacy of protease inhibitors againstHCVgenotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 141: 1067-1079. http://dx.doi.org/10.1053/j.gastro.2011.06.004.
6. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. 2011. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 140: 1032-1042. http://dx.doi.org/10.1053/j.gastro.2010.11.036.
7. Li YP, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J. 2014. Differential sensitivity of 5=UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Gastroenterology 146: 812-821. http://dx.doi.org/10.1053/j.gastro.2013.11.009.
8. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P. 2010. The neglected hepatitis C virus genotypes 4, 5 and 6: An international consensus report. Liver Int 30: 342-355. http://dx.doi.org/10 .1111/j.1478-3231.2009.02188.x.
9. Vermehren J, Sarrazin C. 2012. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 26: 487-503. http://dx.doi.org/10.1016/j .bpg.2012.09.011.
10. Schneider MD, Sarrazin C. 2014. Antiviral therapy of hepatitis C in 2014: Do we need resistance testing? Antiviral Res 105: 64-71. http://dx.doi.org/10.1016/j.antiviral.2014.02.011.
11. Imhof I, Simmonds P. 2010. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6. J Virol 84: 4597-4610. http://dx.doi.org/10.1128/JVI.02698-09.
12. Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC, Simmen KA. 2010. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 54: 1878-1887. http://dx.doi.org/10.1128/AAC.01452-09.
13. Cheng G, Chan K, Yang H, Corsa A, Pokrovskii M, Paulson M, Bahador G, Zhong W, Delaney W. 2011. Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system. Antimicrob Agents Chemother 55: 2197-2205. http://dx.doi .org/10.1128/AAC.01382-10.
14. Foster GR, Hezode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M. 2011. Telaprevir alone or with peginterferon and ribavirin reducesHCVRNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 141: 881-889. http://dx.doi.org/10.1053/j.gastro.2011.05.046.
15. Imhof I, Simmonds P. 2011. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 53: 1090-1099. http://dx.doi.org/10.1002/hep.24172.
16. De Meyer S, Ghys A, Foster GR, Beumont M, Van BB, Lin TI, Dierynck I, Ceulemans H, Picchio G. 2013. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. J Viral Hepat 20: 395-403. http://dx.doi.org/10.1111/jvh.12046.
17. Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TK, Serre SB, Mikkelsen L, Bukh J. 2013. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses. Antimicrob Agents Chemother 57: 1291-1303. http://dx.doi.org/10.1128/AAC.02164-12.
18. Lenz O, Vijgen L, Berke JM, Cummings MD, Fevery B, Peeters M, De Smedt G, Moreno C, Picchio G. 2013. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 58: 445-451. http://dx.doi.org/10.1016/j.jhep.2012.10.028.
19. Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, Gupta S, Hughes E, Chase R, Lahser F, Barnard RJ, Howe AY, Howe JA. 2013. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. J Hepatol 59: 31-37. http://dx.doi.org/10.1016/j.jhep.2013.02.018.
20. Bronowicki JP, Ratziu V, Gadano A, Thuluvath PJ, Bessone F, Martorell CT, Pol S, Terg R, Younes Z, He B, Eley T, Cohen D, Yu F, Hernandez D, McPhee F, Mendez P, Hughes E. 2014. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. J Hepatol 61: 1220-1227. http://dx.doi.org/10.1016/j.jhep.2014.07.011.
21. Lawitz E, Sullivan G, Rodriguez-Torres M, Bennett M, Poordad F, Kapoor M, Badri P, Campbell A, Rodrigues L, Jr, Hu Y, Pilot-Matias T, Vilchez RA. 2015. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect 70: 197-205. http://dx.doi.org/10.1016/j.jinf.2014.09.008.
22. Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L, Jr, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Kumada H. 2015. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology 61: 1523-1532. http://dx.doi.org/10.1002/hep.27705.
23. Moreno C, Hezode C, Marcellin P, Bourgeois S, Francque S, Samuel D, Zoulim F, Grange JD, Shukla U, Lenz O, Ouwerkerk-Mahadevan S, Fevery B, Peeters M, Beumont M, Jessner W. 2015. Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J Hepatol 62: 1047-1055. http://dx .doi.org/10.1016/j.jhep.2014.12.031.
24. Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer- Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S. 2015. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatmentexperienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): A randomised, open-label trial. Lancet 385: 2502-2509. http://dx.doi.org/10.1016/S0140-6736(15)60159-3.
25. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. 2015. Grazoprevir-elbasvir combination therapy for treatment- naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial. Ann Intern Med 163: 1-13. http://dx.doi.org/10.7326/M15-0785.
26. Kumada H, Sato K, Takehara T, Nakamuta M, Ishigami M, Chayama K, Toyota J, Suzuki F, Nakayasu Y, Ochi M, Yamada I, Okanoue T. 2015. Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan. Hepatol Res 45: 745-754. http://dx.doi.org/10.1111/hepr.12416.
27. Besse B, Coste-Burel M, Bourgeois N, Feray C, Imbert-Marcille BM, Andre-Garnier E. 2012. Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method. J Virol Methods 185: 94-100. http://dx.doi .org/10.1016/j.jviromet.2012.06.011.
28. Paolucci S, Fiorina L, Piralla A, Gulminetti R, Novati S, Barbarini G, Sacchi P, Gatti M, Dossena L, Baldanti F. 2012. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J 9: 245. http://dx.doi.org/10.1186/1743-422X-9-245.
29. Alves R, Queiroz AT, Pessoa MG, da Silva EF, Mazo DF, Carrilho FJ, Carvalho-Filho RJ, de Carvalho IM. 2013. The presence of resistance mutations to protease and polymerase inhibitors in hepatitis C virus sequences from the Los Alamos databank. J Viral Hepat 20: 414-421. http://dx.doi.org/10.1111/jvh.12051.
30. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309: 623-626. http://dx.doi.org/10.1126/science.1114016.
31. Li YP, Ramirez S, Jensen SB, Purcell RH, Gottwein JM, Bukh J. 2012. Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc Natl Acad SciUSA109: 19757-19762. http://dx .doi.org/10.1073/pnas.1218260109.
32. Sakai A, Takikawa S, Thimme R, Meunier JC, Spangenberg HC, Govindarajan S, Farci P, Emerson SU, Chisari FV, Purcell RH, Bukh J. 2007. In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells. J Virol 81: 7208-7219. http://dx.doi.org/10.1128/JVI.01774-06.
33. Yanagi M, Purcell RH, Emerson SU, Bukh J. 1999. Hepatitis C virus: An infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology 262: 250-263. http://dx .doi.org/10.1006/viro.1999.9889.
34. Kato T, Furusaka A, Miyamoto M, Date T, Yasui K, Hiramoto J, Nagayama K, Tanaka T, Wakita T. 2001. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol 64: 334-339. http://dx.doi.org/10.1002/jmv.1055.
35. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 103: 7408-7413. http://dx.doi.org/10.1073/pnas.0504877103.
36. Gottwein JM, Scheel TK, Callendret B, Li YP, Eccleston HB, Engle RE, Govindarajan S, Satterfield W, Purcell RH, Walker CM, Bukh J. 2010. Novel infectious cDNA clones of hepatitisCvirus genotype 3a (strain S52) and 4a (strain ED43): Genetic analyses and in vivo pathogenesis studies. J Virol 84: 5277-5293. http://dx.doi.org/10.1128/JVI.02667-09.
37. Gottwein JM, Scheel TK, Hoegh AM, Lademann JB, Eugen-Olsen J, Lisby G, Bukh J. 2007. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 133: 1614-1626. http://dx.doi.org/10.1053/j.gastro.2007.08.005.
38. Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, Miller V. 10 June 2015. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology. http://dx.doi.org/10.1002/hep.27934.
39. Lohmann V, Bartenschlager R. 2014. On the history of hepatitis C virus cell culture systems. J Med Chem 57: 1627-1642. http://dx.doi.org/10 .1021/jm401401n.
40. Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J. 2009. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49: 364-377. http://dx.doi.org/10.1002/hep.22673.
41. Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J. 2011. MicroRNA- 122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5= UTR. Proc Natl Acad Sci U S A 108: 4991-4996. http://dx.doi.org/10.1073/pnas .1016606108.
42. Gottwein JM, Jensen SB, Serre SB, Ghanem L, Scheel TK, Jensen TB, Krarup H, Uzcategui N, Mikkelsen LS, Bukh J. 2013. Adapted J6/JFH1- based hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor. Antimicrob Agents Chemother 57: 6034-6049. http://dx.doi.org/10.1128/AAC.01176-13.
43. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796. http://dx.doi .org/10.1038/nm1268.
44. Li YP, Ramirez S, Gottwein JM, Scheel TK, Mikkelsen L, Purcell RH, Bukh J. 2012. Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proc Natl Acad Sci U S A 109: E1101-E1110. http://dx.doi.org/10.1073/pnas.1203829109.
45. Ramirez S, Li YP, Jensen SB, Pedersen J, Gottwein JM, Bukh J. 2014. Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. Hepatology 59: 395-407. http://dx.doi.org/10 .1002/hep.26660.
46. Li YP, Ramirez S, Mikkelsen LS, Bukh J. 2015. Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77. J Virol 89: 811-823. http://dx.doi.org/10.1128/JVI.02877-14.
47. Russell RS, Meunier JC, Takikawa S, Faulk K, Engle RE, Bukh J, Purcell RH, Emerson SU. 2008. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci U S A 105: 4370-4375. http://dx.doi.org/10.1073/pnas.0800422105.
48. Date T, Kato T, Kato J, Takahashi H, Morikawa K, Akazawa D, Murayama A, Tanaka-Kaneko K, Sata T, Tanaka Y, Mizokami M, Wakita T. 2012. Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone. J Virol 86: 10805-10820. http://dx.doi.org/10.1128/JVI.07235-11.
49. Yamane D, McGivern DR, Wauthier E, Yi M, Madden VJ, Welsch C, Antes I, Wen Y, Chugh PE, McGee CE, Widman DG, Misumi I, Bandyopadhyay S, Kim S, Shimakami T, Ikawa T, Whitmire JK, Heise MT, Dittmer DP, Kao CC, Pitson SM, Merrill AHJ, Reid LM, Lemon SM. 2014. Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. Nat Med 20: 927-935. http://dx.doi.org/10.1038/nm.3610.
50. Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ, Huang W, Schiffer CA. 2012. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog 8: E1002832. http://dx.doi.org/10.1371/journal.ppat.1002832.
51. Lim SR, Qin X, Susser S, Nicholas JB, Lange C, Herrmann E, Hong J, Arfsten A, Hooi L, Bradford W, Najera I, Smith P, Zeuzem S, Kossen K, Sarrazin C, Seiwert SD. 2012. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob Agents Chemother 56: 271-279. http://dx.doi.org/10.1128/AAC.05636-11.
52. Shimakami T, Welsch C, Yamane D, McGivern DR, Yi M, Zeuzem S, Lemon SM. 2011. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology 140: 667-675. http://dx.doi.org/10.1053/j.gastro.2010.10.056.
53. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132: 1767-1777. http://dx.doi.org/10.1053/j.gastro .2007.02.037.
54. Aloia AL, Eyre NS, Black S, Bent SJ, Gaeguta A, Guo Z, Narayana SK, Chase R, Locarnini S, Carr JM, Howe JA, Beard MR. 2015. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations. Antivir Ther 20: 271-280. http://dx.doi.org/10.3851/IMP2850.
55. Combet C, Garnier N, Charavay C, Grando D, Crisan D, Lopez J, Dehne-Garcia A, Geourjon C, Bettler E, Hulo C, Le MP, Bartenschlager R, Diepolder H, Moradpour D, Pawlotsky JM, Rice CM, Trepo C, Penin F, Deleage G. 2007. euHCVdb: The European hepatitis C virus database. Nucleic Acids Res 35: D363-D366. http://dx.doi.org/10.1093/nar/gkl970.
56. Kuiken C, Hraber P, Thurmond J, Yusim K. 2008. The hepatitis C sequence database in Los Alamos. Nucleic Acids Res 36: D512-D516. http://dx.doi.org/10.1093/nar/gkm962.
57. Ampuero J, Romero-Gomez M, Reddy KR. 2014. Review article: HCV genotype 3-the new treatment challenge. Aliment Pharmacol Ther 39: 686-698. http://dx.doi.org/10.1111/apt.12646.
58. Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, DiMuzio JM, Ferrara M, Di FM, Gates AT, Graham DJ, Harper S, Hazuda DJ, McHale C, Monteagudo E, Pucci V, Rowley M, Rudd MT, Soriano A, Stahlhut MW, Vacca JP, Olsen DB, Liverton NJ, Carroll SS. 2012. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56: 4161-4167. http://dx.doi.org/10 .1128/AAC.00324-12.